Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 5/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4389979 | 0.92 | PDE2A (0.49) | PDE2AALDH1A1GPR139ENPP2 | |
| SCHEMBL5668567 | 0.92 | PDE2A (0.47) | PDE2AALDH1A1GPR139 | |
| SCHEMBL5668017 | 0.86 | ALDH1A1 (0.44) | PDE2AALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4383435 | 0.84 | ALDH1A1 (0.42) | PDE2AALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4394123 | 0.84 | ALDH1A1 (0.41) | PDE2AALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4390778 | 0.83 | ALDH1A1 (0.42) | PDE2AALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL4392327 | 0.83 | HDAC3 (0.42) | PDE2AALDH1A1GPR139KMT2A | |
| SCHEMBL5670705 | 0.81 | ALDH1A1 (0.40) | PDE2AALDH1A1GPR139KMT2ASMN1; SMN2 | |
| SCHEMBL4387739 | 0.81 | ALDH1A1 (0.42) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL2172250 | 0.81 | MEN1 (0.45) | ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | PDE2A 1806/4885ALDH1A1 1466/4885GPR139 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.